The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The company operates a chain of mid-sized multi-speciality hospitals
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Subscribe To Our Newsletter & Stay Updated
